Company Overview - Korro Bio, Inc. is a biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases [3] - The company utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs aimed at achieving precise and transient single base edits [3] - By editing RNA instead of DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to increased specificity and improved long-term tolerability [3] Upcoming Events - Ram Aiyar, Ph.D., CEO and President of Korro, will present at the Jefferies London Healthcare Conference on November 19, 2024, at 8:00 a.m. GMT [1] - Vineet Agarwal, CFO, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in the conference [1] - A live webcast of the presentation will be available on Korro's website, with a replay accessible for 30 days following the event [2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | --- | --- | --- | |---------------------------|-----------|-------------------------------------------------------| | | | | | | Trading | | | Title of each class | Symbol(s) | Name of each exchange on which registered | FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

-Regulatory filing of Phase 1/2 clinical study for Alpha-1 Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 -First participant dosing anticipated in first quarter of 2025 -Interim readout expected in second half of 2025 and completion of Phase 1/2 study anticipated in 2026 CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), ...

Shares of Korro Bio, Inc. (KRRO) have gained 6.7% over the past four weeks to close the last trading session at $39.76, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $135 indicates a potential upside of 239.5%. The mean estimate comprises five short-term price targets with a standard deviation of $42.13. While the lowest estimate of $95 indicates a 138.9% increase from the cur ...

CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced one oral and two poster presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal taking place on October 6-9, 2024. Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral ...

CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor and scientific conferences: 2024 Wells Fargo Healthcare Conference Chief Executive Officer and President, Ram Aiyar, Ph.D., and Chief Financial Officer, Vineet Agarwal, will participate ...

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, is presenting new preclinical data demonstrating the specificity and the completion of a genetic mouse study and sustained editing activity for KRRO-110, its development candidate for the treatment of AATD. New data for KRRO-110 shows approximately 60% editing efficiency and greater than 60µM ...

Core Insights - Korro Bio, Inc. is advancing its development candidate KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD), showcasing promising preclinical data [1][3] - The company is on track to submit a regulatory filing for a first-in-human study of KRRO-110 in AATD patients in the second half of 2024 [3] Preclinical Data - KRRO-110 demonstrated approximately 60% editing efficiency and increased total AAT protein levels to greater than 60µM at week 13, with previous data showing efficacy up to week 9 [2][6] - The study included a non-human primate surrogate test article, supporting species translation towards human dose projections [2] AATD Overview - AATD is an inherited genetic disorder primarily caused by a mutation in the SERPINA1 gene, with over 95% of severe cases being homozygous for the PiZ mutation [4] - The condition can lead to severe lung and liver diseases, affecting an estimated 3.4 million individuals globally [4] Company Background - Korro Bio focuses on developing a new class of genetic medicines using its proprietary RNA editing platform, aiming to provide precise and transient single base edits [5] - The company is based in Cambridge, Massachusetts, and is leveraging established regulatory pathways for oligonucleotide drugs to bring its medicines to patients [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 One Kendall Square, Building 600-700, Suite 6-401 Cambridge, MA 02139 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-39062 Korro B ...

Exhibit 99.1 Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 — Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024, and provided an update on its recent progress and anticipated milestones. • Appointed Dr. Kemi Olug ...